enzalutamide,olaparib,177lu-psma-617
pfizer,merck,novartis,astellas,astrazeneca
['propel', 'arches', 'prostate', ' vision', 'vision trial']
in case you missed the #esmo2022 prostate cancer posters here were mine from and arches, propel, and vision trials: 
Professor of Medicine, Surgery, Pharmacology and Cancer Biology, Duke Cancer Institute, Durham NC